Legend Biotech(LEGN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached $306 million, representing a 64% year-over-year growth [22] - Gross margin remained strong at 61%, with CARVYKTI net product sales gross margin at 57% [22] - Operating margin improved from -142% in Q2 2023 to -6% in Q4 2025, reflecting operational leverage [22][24] - Adjusted net income was reported at $2.5 million, a significant improvement from a $59 million adjusted net loss a year ago [24] Business Line Data and Key Metrics Changes - CARVYKTI net trade sales were approximately $555 million in Q4 2025, a 66% increase year-over-year [5][14] - U.S. net trade sales of CARVYKTI were $420 million, growing 38% year-over-year [14] - Outside the U.S., sales reached $135 million, representing over a threefold increase compared to the same period last year [14] Market Data and Key Metrics Changes - CARVYKTI is now offered in 14 global markets, with 294 treatment sites worldwide [14] - The majority of CARVYKTI patients (approximately 65%) are from the second to fourth line settings [14][76] - BCMA-directed therapies remain under-penetrated in earlier lines, with less than 5% of patients in the second through fourth line treated with a BCMA targeting agent in 2025 [15] Company Strategy and Development Direction - The company aims to achieve company-wide profitability in 2026, following CARVYKTI's profitability in 2025 [5][13] - Focus on expanding CARVYKTI's use in earlier treatment lines, supported by clinical evidence showing better outcomes [15][20] - Plans to file one to two U.S. INDs by the end of the year and to explore synergistic business development opportunities [12][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sequential growth throughout 2026, targeting approximately 50% top-line growth for CARVYKTI [30] - The company is optimistic about capturing a significant market share in the under-penetrated multiple myeloma market [15][45] - Management highlighted the importance of effective bridging therapy in improving patient outcomes and safety [19][90] Other Important Information - The company ended the year with $949 million in cash equivalents, providing flexibility for future investments [25] - Manufacturing capacity has been expanded to support annual production of 10,000 doses, with plans to increase to 20,000 doses [11][52] Q&A Session Summary Question: Expectations for CARVYKTI growth in 2026 and business development focus - Management expects sequential growth throughout 2026, confident in achieving approximately 50% top-line growth [30] - Business development efforts will focus on complementary technologies and potential partnerships to accelerate global development [31] Question: Positioning of bispecifics in early lines relative to CARVYKTI - Management noted a significant unmet need in second and third lines, with CARVYKTI's unique value proposition supporting its growth in these settings [34] Question: Community setting expansion hurdles - Continued education and training for community physicians are essential for expanding CARVYKTI's adoption in community hospitals [39][40] Question: Current CAR-T penetration targets - Management believes there is significant growth potential in both late and early lines, with plans to increase annual supply to meet demand [45][47] Question: Competitive dynamics following recent M&A in the space - The acquisition of a competitor validates the market's value, with management confident in CARVYKTI's unmatched efficacy and durability [59][61] Question: Pipeline strategy and in vivo programs - The company is particularly excited about in vivo CAR T approaches due to their convenience and potential for broader applications [82]